News

FDA Invites Patient Organizations to Organize Public Meetings to Enhance Awareness of Their Needs


 

References

In 2012 legislation known as the FDA Safety and Innovation Act, the Food and Drug Administration was authorized to conduct a series of 20 public meetings focusing on specific diseases to enhance understanding of the patient experience. Now, the FDA has announced that patient organizations whose diseases were not included in this series may organize their own meetings for this purpose. Learn more about this in an FDA blog and on the FDA website.

Recommended Reading

Experts call for international cooperation on human gene editing
MDedge Dermatology
EADV: Fresh insights into Gorlin syndrome
MDedge Dermatology
NORD Publishes Report on Pachyonychia Congenita
MDedge Dermatology
NORD Publishes Report on Pachyonychia Congenita
MDedge Dermatology
EADV: Fresolimumab shows early promise in scleroderma
MDedge Dermatology
NIH Launches Online Application Portal for Undiagnosed Diseases Network
MDedge Dermatology
Patient Organizations May Apply to Join Natural History Study Project
MDedge Dermatology
Rare Disease Community Prepares for Worldwide Observance of Rare Disease Day
MDedge Dermatology
Omnibus Spending Bill Includes Provisions Important to the Rare Disease Community
MDedge Dermatology
Consider pyoderma gangrenosum for nonhealing wounds
MDedge Dermatology